NCT03300492View on ClinicalTrials.gov

Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
OTHER

NK-DLI

"Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at \<1x105/kg."

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER